News | February 29, 2012

Lantheus Announces Partnership for Distribution of Definity Echo Contrast in China

Lantheus Announces Partnership for Distribution of Definity Echo Contrast in China

Illustration of Definity use in Apical 4 Chamber imaging

February 29, 2012 — Lantheus Medical Imaging Inc. announced a strategic distribution arrangement for its Definity cardiac ultrasound contrast agent in the People’s Republic of China, including Hong Kong S.A.R. and Macau S.A.R.

The board of directors for both Lantheus and Beijing Double-Crane Pharmaceutical Company Ltd., a leading pharmaceutical company based in Beijing, have approved a 15-year agreement for exclusive distribution and supply of Definity, an ultrasound contrast agent for use in echocardiograms. This agreement expands global access to Definity in a key geographic region. Definity is currently approved in North America, Europe, and a number of other countries. Lantheus and Double-Crane plan to fully execute the agreement in the next several weeks in China.

Under the terms of the agreement, both parties will collaborate on confirmatory clinical trials to commercialize Definity in China for use in cardiac disease. Double-Crane will conduct the clinical trials once the design has been agreed upon with Lantheus, and Lantheus will provide regulatory support and product for the trials. Lantheus and Double-Crane will work together to develop new indications.

The agreement also provides Double-Crane the right of first negotiation to manufacture Definity in China upon the achievement of certain sales levels. In addition, Double-Crane has the right to negotiate the manufacture of Definity in China in the event Lantheus chooses to seek a Chinese manufacturing partner for the product.

“The distribution and supply agreement with Double-Crane supports our commitment to global expansion to help improve the treatment of human disease in key international markets,” said Don Kiepert, president and CEO, Lantheus Medical Imaging. “Definity is an important diagnostic tool that can provide critical patient information to help physicians make more informed patient management decisions. We are pleased to announce this agreement to enter the Chinese market and look forward to working closely with such an esteemed partner as Double-Crane to make Definity available to both physicians and patients in China.”

Double-Crane is focused on the development of products in the area of cardiovascular disease. This partnership with Lantheus is part of Double-Crane’s strategic development plan in support of China’s “National 12th Five-Year Development Program.” This partnership will support Double-Crane in achieving its objective to enhance its product pipeline with a globally branded drug, such as Definity.

“We are very pleased to be the exclusive distributor of Definity in China,” said Li Xin, president of Double-Crane. “Distribution of Definity into China will significantly help Chinese physicians to diagnose diseases and provides a new tool for the management of patient care. We believe Definity will also bring a great economic outcome in health care management in China. In addition, Definity will play an important role in the portfolio of cardiovascular products of Double-Crane. The exclusive distribution and supply of Definity will enhance our competitive advantage in the area of cardiovascular diseases.”

For more information: www.definityimaging.com

Related Content

Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Hitachi Medical Systems Europe Introduces Third-Generation Intelligent Vector Flow Mapping
News | Cardiovascular Ultrasound | December 07, 2018
Hitachi Medical Systems Europe introduced what it calls the next level of intelligent Vector Flow Mapping (iVFM) at...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...
Guerbet Showcases Ongoing Collaboration With IBM Watson at RSNA 2018
News | Clinical Decision Support | November 21, 2018
Guerbet LLC USA will feature its digital solutions including its ongoing collaboration with IBM Watson Health in...
Bay Labs and Northwestern Medicine Enroll First Patient in AI Echocardiography Study
News | Cardiovascular Ultrasound | November 19, 2018
Medical artificial intelligence (AI) company Bay Labs and Northwestern Medicine announced that the first patient has...
Voyageur Minerals to Begin Manufacturing Barium Contrast Products With Chief Medical Supply
News | Contrast Media | November 14, 2018
Voyageur Minerals Ltd. signed a joint venture agreement with Chief Medical Supply Ltd (CM) of Calgary, Alberta to...